Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An invasive transitional cell carcinoma of the bladder that exhibits spindle cell sarcomatoid features.
Biomarker and diagnostic research for infiltrating bladder urothelial carcinoma sarcomatoid variant has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE2, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
155 publications have been identified in PubMed for infiltrating bladder urothelial carcinoma sarcomatoid variant. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (26%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 48 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:26 AM UTC
31%
Laboratory research | 41 | 26% |
Clinical study results | 23 | 15% |
Testing and diagnosis research | 15 | 10% |
Patient case studies | 12 | 8% |
Disease patterns and progression | 12 | 8% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
Zhou ZH (2026). [PMID: 41274398](https://pubmed.ncbi.nlm.nih.gov/41274398/). *Cancer Lett*. [Basic Science / Preclinical]
Basar M (2026). [PMID: 41609241](https://pubmed.ncbi.nlm.nih.gov/41609241/). *Adv Anat Pathol*. [Review / Meta-Analysis]
Lopez-Beltran A (2026). [PMID: 41505638](https://pubmed.ncbi.nlm.nih.gov/41505638/). *Current opinion in urology*. [Review / Meta-Analysis]
Ricciardi G (2026). [PMID: 41422765](https://pubmed.ncbi.nlm.nih.gov/41422765/). *Clinical genitourinary cancer*. [Review / Meta-Analysis]
Cheville JC (2026). [PMID: 41173324](https://pubmed.ncbi.nlm.nih.gov/41173324/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Basic Science / Preclinical]
Seebold A (2026). [PMID: 40504254](https://pubmed.ncbi.nlm.nih.gov/40504254/). *Urologie*. [Case Report / Case Series]
Ertoy-Baydar D (2026). [PMID: 41318992](https://pubmed.ncbi.nlm.nih.gov/41318992/). *Curr Opin Urol*. [Review / Meta-Analysis]
Akbulut D (2026). [PMID: 41384692](https://pubmed.ncbi.nlm.nih.gov/41384692/). *Histopathology*. [Review / Meta-Analysis]
Downes MR (2026). [PMID: 41384703](https://pubmed.ncbi.nlm.nih.gov/41384703/). *Histopathology*. [Review / Meta-Analysis]
Wu DJ (2026). [PMID: 41650796](https://pubmed.ncbi.nlm.nih.gov/41650796/). *Seminars in diagnostic pathology*. [Diagnostic / Biomarker]